Archive

The British Academy is the UK’s national academy for the humanities and social sciences. We mobilise these disciplines to understand the world and shape a brighter future.

The Academic-Industry Research Network—theAIRnet—is a 501(c)(3) not-for-profit research organization devoted to the proposition that a sound understanding of the role of business in the economy requires collaboration between academic scholars and industry experts.

SOAS is home to the leading research and expertise on the global issues of today.

Bernanke and Blanchard have made another failed attempt to salvage establishment macroeconomics after the massive onslaught of adverse inflationary circumstances with which it could evidently not contend.

How convincing is the model analysis by Bernanke and Blanchard? How empirically relevant are their mechanisms causing inflation – and how robust and plausible are their econometric findings?

Behind bogus promises of job creation and economic growth lies a dangerous agenda to shred social safety nets.

Your health shouldn’t be someone else’s wealth.

A Rolling Stone article by Andrew Perez cited Fred Ledley’s INET working paper on the NIH seed funding of pharmaceuticals.

Programs for expedited review may be preferentially reducing the development costs for conditions with lesser disease burden, potentially making investments in addressing the most significant disease burdens even less appealing and exacerbating the market failure further.

Do temporary economic shocks like the COVID-19 recession create lasting effects on the economy?

The discrepancy between technocratic rhetoric and economic facts is colossal.

Industry lobbyists vehemently oppose Medicare drug price negotiations. However, physician-scientist Fred Ledley and economist William Lazonick debunk their arguments.

How the dark side of consumer finance prioritizes profit over people.

The Uncertainty of Retirement in the New Economy

The “maximum fair price” for a drug must not only be equitable to those with unmet medical needs who may benefit from the use of the drug but also provide equitable returns on both public and private sector investments.